Dyne Therapeutics, Inc. (DYN) Shows 12-Month Functional Gains in DM1; REC Topline Expected Q1 2027

Dyne Therapeutics reported 12-month pooled MAD data for z-basivarsen (DYNE-101) in DM1 showing functional improvement vs baseline, placebo and a matched natural history cohort. The REC’s primary endpoint is 6-month vHOT; topline is expected in Q1 2027.Material DetailsContext by AI AnalystThis is mi…